机译:CD163阳性肿瘤相关的巨噬细胞和CD8阳性细胞毒性淋巴细胞是骨肉瘤患者治疗分层的强大诊断标志:来自法国OS2006阶段3试验的活组织检查的免疫组化分析
CHU Toulouse IUCT Oncopole Dept Pathol Toulouse France;
CHU Toulouse IUCT Oncopole Dept Pathol Toulouse France;
IUCT Oncopole Claudius Regaud Inst Biostat Unit Toulouse France;
CHU Timone Dept Pathol Marseille France;
CHRU Lille Dept Pathol Lille France;
Curie Inst Dept Pathol Paris France;
CHU Nancy Dept Pathol Nancy France;
Hop Cochin AP HP Serv Pathol Paris France;
Hautepierre Pediat Oncol Dept Strasbourg France;
CHU Tours Dept Pathol Tours France;
IUCT Oncopole Claudius Regaud Inst Biostat Unit Toulouse France;
Dept Children &
Adolescents Oncol Gustave Roussy Canc Campus Villejuif France;
Univ Paul Sabatier Med Sch Rangueil Toulouse France;
Hop Necker Enfants Malad Dept Pediat Orthoped Surg Paris France;
Univ Nantes INSERM UMR1238 Nantes France;
Unicancer Paris France;
Biostat Unit Gustave Roussy Canc Campus Villejuif France;
Curie Inst Dept Med Oncol Paris France;
Univ Nantes INSERM UMR1238 Nantes France;
Univ Nantes INSERM UMR1238 Nantes France;
CD8; CD163; macrophages; Osteosarcoma; PD1; PDL-1 Checkpoint;
机译:CD163阳性肿瘤相关的巨噬细胞和CD8阳性细胞毒性淋巴细胞是骨肉瘤患者治疗分层的强大诊断标志:来自法国OS2006阶段3试验的活组织检查的免疫组化分析
机译:参与IBCSG III期随机临床试验的三阴性乳腺癌患者中,肿瘤浸润淋巴细胞(TIL)是强大的预后指标22-00
机译:在一项初步的I期临床试验中,采用长春瑞滨膀胱内治疗的浅表性膀胱肿瘤患者的Ki-67,p21waf1 / cip1和标志物病灶的免疫组织化学分析。
机译:CD163阳性肿瘤相关巨噬细胞和CD8阳性细胞毒性淋巴细胞是骨肉瘤患者治疗分层的有力诊断标志物:法国OS2006 3期试验对活检组织的免疫组织化学分析